المؤلفون: Vladimir V. Evdokimov, Anna G. Evdokimova, Raisa I. Stryuk, Elena N. Yushchuk, Natalia O. Kuvyrdina, Galina V. Voronina

المصدر: КардиоСоматика, Vol 14, Iss 1, Pp 17-26 (2023)

مصطلحات موضوعية: aclidinium bromide, chronic heart failure, chronic obstructive pulmonary disease, eplerenone, formoterol, ischemic heart disease, losartan, nebivolol, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://cardiosomatics.orscience.ru/2221-7185/article/viewFile/248417/pdf_1Test; https://doaj.org/toc/2221-7185Test; https://doaj.org/toc/2658-5707Test

الوصول الحر: https://doaj.org/article/ea00c4de37bf4daa81eb93a98a4f8b5eTest

المؤلفون: Sergey K. Zyryanov, Ilya N. Dyakov, Zaurbek R. Aisanov

المصدر: Терапевтический архив, Vol 94, Iss 7, Pp 850-858 (2022)

مصطلحات موضوعية: pharmacoeconomics, budget impact analysis, asthma, mild asthma, moderate to severe asthma, budesonide/formoterol, salbutamol, salmeterol/fluticasone, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/109735/83978Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/c1063269fecf4bc99a26d71b1ef8be46Test

المؤلفون: E. A. Orlova, I. P. Dorfman, M. A. Orlov, M. A. Abdullaev

المصدر: Медицинский совет, Vol 0, Iss 4, Pp 128-137 (2022)

مصطلحات موضوعية: chronic obstructive pulmonary disease, glycopyrronium bromide, formoterol fumarate, aerosphere, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6777Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/94fa093ebf164e40a945a546c37eeea4Test

المؤلفون: O. N. Titova, N. A. Kuzubova, A. G. Kozyrev, A. A. Shumilov, О. Н. Титова, Н. А. Кузубова, А. Г. Козырев, А. А. Шумилов

المساهمون: The study had no funding or sponsorship, Исследование не имело финансирования и спонсорской поддержки

المصدر: PULMONOLOGIYA; Том 33, № 1 (2023); 44-50 ; Пульмонология; Том 33, № 1 (2023); 44-50 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: формотерола фурамат, aclidinium bromide, formoterol fumarate, аклидиния бромид

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/4190/3494Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4190/1698Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4190/1765Test; Lamprecht B., McBurnie M.A., Vollmer W.M. et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–763. DOI:10.1378/chest.10-1253.; World Health Organization. The top 10 causes of death. 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10causes-of-deathTest; Casale R., Pasqualetti P. Cosinor analysis of circadian peak expiratory flow variability in normal subjects, passive smokers, heavy smokers, patients with chronic obstructive pulmonary disease and patients with interstitial lung disease. Respiration. 1997; 64 (4): 251–256. DOI:10.1159/000196682.; Kessler R., Partridge M.R., Miravitlles M. et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur. Respir. J. 2011; 37 (2): 264–272. DOI:10.1183/09031936.00051110.; Stephenson J.J., Cai Q., Mocarski M. et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 577–586. DOI:10.2147/COPD.S76157.; Roche N., Small M., Broomfield S. et al. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013; 10 (6): 679–686. DOI:10.3109/15412555.2013.844784.; Tsiligianni I., Metting E., van der Molen T. et al. Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim. Care Respir. Med. 2016; 26: 16040. DOI:10.1038/npjpcrm.2016.40.; Sun T., Li X., Cheng W. et al. The relationship between morning symptoms and the risk of future exacerbations in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15: 1899–1907. DOI:10.2147/COPD.S255030.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022 Report. Available at: https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022v1.0-12Nov2021_WMV.pdfTest; Министерство здравоохранения Российской Федерации. Хроническая обструктивная болезнь легких: клинические рекомендации. 2021. Доступно на: https://cr.minzdrav.gov.ru/recomend/603_2Test; Lopez-Campos J.L., Calero-Acuña C., Márquez-Martín E. et al. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1867–1876. DOI:10.2147/COPD.S132962.; Oba Y., Keeney E., Ghatehorde N., Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2018; 12 (12): CD012620. DOI:10.1002/14651858.CD012620.pub2.; Di Marco F., Santus P., Scichilone N. et al. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy. Respir. Med. 2017; 125: 49–56. DOI:10.1016/j.rmed.2017.03.001.; Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10 (4): 511–522. DOI:10.3109/15412555.2013.814626.; Rogliani P., Calzetta L., Ora J. et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur. J. Pharmacol. 2015; 761: 383–390. DOI:10.1016/j.ejphar.2015.04.042.; Medic G., Lindner L., van der Weijden M., Karabis A. Efficacy and safety of Aclidinium/Formoterol versus Tiotropium in COPD: results of an indirect treatment comparison. Adv. Ther. 2016; 33 (3): 379–399. DOI:10.1007/s12325-016-0299-4.; Kostikas K., Dimakou K., Gourgoulianis K. et al. A real-world study on the day and night-time symptoms among greek COPD patients who recently initiated treatment with dual bronchodilation: the DANICO study. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2027–2041. DOI:10.2147/COPD.S367553.; Kamei T., Nakamura H., Nanki N. et al. Clinical benefit of twotimes-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study. BMJ Open. 2019; 9 (7): e024114. DOI:10.1136/bmjopen-2018-024114.; Bateman E.D., Chapman K.R., Singh D. et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir. Res. 2015; 16 (1): 92. DOI:10.1186/s12931-015-0250-2.; van Buul A.R., Kasteleyn M.J., Chavannes N.H., Taube C. Association between morning symptoms and physical activity in COPD: a systematic review. Eur. Respir. Rev. 2017; 26 (143): 160033. DOI:10.1183/16000617.0033-2016.; Miravitlles M., Menezes A., López Varela M.V. et al. Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: the LASSYC observational study. Respir. Med. 2018; 134: 62–69. DOI:10.1016/j.rmed.2017.11.018.; Núñez A., Esquinas C., Barrecheguren M. et al. Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3837–3844. DOI:10.2147/COPD.S179402.; Celli B., Tetzlaff K., Criner G. et al. The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD biomarker qualification consortium. Am. J. Respir. Crit. Care Med. 2016; 194 (12): 1483–1493. DOI:10.1164/rccm.201508-1653OC.; Puhan M.A., Mador M.J., Held U. et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur. Respir. J. 2008; 32 (3): 637–643. DOI:10.1183/09031936.00140507.; Magnussen H., Watz H., Zimmermann I. et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir. Med. 2009; 103 (12): 1832–1837. DOI:10.1016/j.rmed.2009.07.006.; Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328. DOI:10.1159/000219676.; Donohue J.F., Soong W., Wu X. et al. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD. Respir. Med. 2016; 116: 41–48. DOI:10.1016/j.rmed.2016.05.007.; Rogliani P., Matera M.G., Ora J. et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 3469–3485. DOI:10.2147/COPD.S146338.; Ni H., Moe S., Soe Z. et al. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018; 12 (12): CD011594. DOI:10.1002/14651858.CD011594.pub2.; Gavaldà A., Ramos I., Carcasona C. et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm. Pharmacol. Ther. 2014; 28 (2): 114–121. DOI:10.1016/j.pupt.2014.05.005.; de la Motte S., Beier J., Schmid K. et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int. J. Clin. Pharmacol. Ther. 2012; 50 (6): 403–412. DOI:10.5414/CP201628.; https://journal.pulmonology.ru/pulm/article/view/4190Test

الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-1-44-50Test
https://doi.org/10.1378/chest.10-1253Test
https://doi.org/10.1159/000196682Test
https://doi.org/10.1183/09031936.00051110Test
https://doi.org/10.2147/COPD.S76157Test
https://doi.org/10.3109/15412555.2013.844784Test
https://doi.org/10.1038/npjpcrm.2016.40Test
https://doi.org/10.2147/COPD.S255030Test
https://doi.org/10.2147/COPD.S132962Test
https://doi.org/10.1002/14651858.CD012620.pub2Test

المؤلفون: E. M. Kostina, E. Yu. Trushina, E. A. Orlova

المصدر: Медицинский совет, Vol 0, Iss 16, Pp 92-98 (2021)

مصطلحات موضوعية: bronchial asthma, covid-19, budesonide, formoterol, glucocorticosteroids, baseline therapy, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6467Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/8cb42abf7ac2472eba8dfe9ff493b786Test

المؤلفون: I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina, N. V. Gordeeva

المصدر: Медицинский совет, Vol 0, Iss 16, Pp 26-31 (2021)

مصطلحات موضوعية: chronic obstructive pulmonary disease, exacerbation, blood eosinophils, long-acting bronchodilators, inhaled corticosteroids, budesonide/formoterol, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6456Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/e5a15ddb94ea4de7b846b8bddaf46d08Test

المؤلفون: I. N. Trofimenko, B. A. Chernyak

المصدر: Медицинский совет, Vol 0, Iss 11, Pp 108-115 (2020)

مصطلحات موضوعية: beclomethasone dipropionate/formoterol, copd, bronchial asthma, small airways, airway inflammation, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/5759Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/4afe90d08e4541e0bf83f4e16aaa4364Test

المؤلفون: Yu. G. Belotserkovskaya, A. G. Romanovskikh, I. P. Smirnov, Ю. Г. Белоцерковская, А. Г. Романовских, И. П. Смирнов

المصدر: Meditsinskiy sovet = Medical Council; № 18 (2022); 122-130 ; Медицинский Совет; № 18 (2022); 122-130 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: порошковый ингалятор, COVID-19 and Asthma, Single Inhaler Maintenance and Reliever Therapy, budesonide/ formoterol, dry powder inhaler, COVID-19 и бронхиальная астма, режим единого ингалятора, будесонид/формотерол

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7130/6402Test; To T., Stanojevic S., Moores G., Gershon A.S., Bateman E.D., Cruz A.A., Boulet L.P. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;(12):204. https://doi.org/10.1186/1471-2458-12-204Test.; Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.xTest.; Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. https://doi.org/10.1016/S0140-6736Test(12)61728-0.; Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. https://doi.org/10.1016/S0140-6736Test(12)61729-2.; Cisneros Serrano C., Melero Moreno C., Almonacid Sánchez C., Perpiñá Tordera M., Picado Valles C., Martínez Moragón E. et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–246. https://doi.org/10.1016/j.arbres.2014.12.007Test.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013Test.; Corne J.M., Marshall C., Smith S., Schreiber J., Sanderson G., Holgate S.T., Johnston S.L. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–834. https://doi.org/10.1016/S0140-6736Test(02)07953-9.; Jackson D.J., Trujillo-Torralbo M.B., del-Rosario J., Bartlett N.W., Edwards M.R., Mallia P. et al. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015;136(2):497–500. https://doi.org/10.1016/j.jaci.2015.01.028Test.; Sykes A., Edwards M.R., Macintyre J., del Rosario A., Bakhsoliani E., Trujillo- Torralbo M.B. et al. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012;129(6):1506–1514. https://doi.org/10.1016/j.jaci.2012.03.044Test.; Wark P.A., Johnston S.L., Bucchieri F., Powell R., Puddicombe S., Laza- Stanca V. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947. https://doi.org/10.1084/jem.20041901Test.; Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026. https://doi.org/10.1038/nm1462Test.; Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. https://doi.org/10.1016/S0140-6736Test(20)30211-7.; Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. https://doi.org/10.1016/j.jaci.2020.04.006Test.; Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K. COVID-19 in critically ill patients in the Seattle region – case series. N Engl J Med. 2020;(382):2012–2022. https://doi.org/10.1056/NEJMoa2004500Test.; Garg S., Kim L., Whitaker M., O`Halloran A., Cummings C., Holstein R. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. https://doi.org/10.15585/mmwr.mm6915e3Test.; Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195–2198. https://doi.org/10.1001/jama.2020.7202Test.; Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–314. https://doi.org/10.1016/j.jaci.2020.06.010Test.; Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. https://doi.org/10.1016/S0140-6736Test(20)31189-2.; Yang M., Zhang Y., Chen H., Lin J., Zeng J., Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection. 2019;47(3):377–385. https://doi.org/10.1007/s15010-018-1229-yTest.; Yang M., Chen H., Zhang Y., Du Y., Xu Y., Jiang P., Xu Z. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29(5):219–226. https://doi.org/10.1080/08958378.2017.1346006Test.; Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7):CD002991. https://doi.org/10.1002/14651858Test.; Contoli M., Pauletti A., Rossi M.R., Spanevellj A., Casolari P., Marcellina A. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. https://doi.org/10.1183/13993003.00451-2017Test.; Yamaya M., Nishimura H., Deng X., Sugawara M., Watanabe O., Nomura K. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. https://doi.org/10.1016/j.resinv.2019.12.005Test.; Matsuyama S., Kawase M., Nao N., Shirato K., Ujike M., Kamitani W. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. https://doi.org/10.1101/2020.03.11.987016Test.; Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. https://doi.org/10.1128/AAC.00819-20Test.; Jackson D.J., Busse W.W., Bacharier L.B., Kattan M., O`Connor G.T., Wood R.A. et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020;146(1):203–206. https://doi.org/10.1016/j.jaci.2020.04.009Test.; Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19 related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83–90. https://doi.org/10.1164/rccm.202003-0821OCTest.; Yang J.M., Koh H.Y., Moon S.Y., Yoo I.K., Ha E.K., You S. et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–798. https://doi.org/10.1016/j.jaci.2020.08.008Test.; Mahdavinia M., Foster K.J., Jauregui E., Andy-Nweye A.B., Khan S. et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2388–2391. https://doi.org/10.1016/j.jaip.2020.05.006Test.; Caminati M., Vultaggio A., Matucci A., Vianello A., Vivarelli E., Crisafulli E. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;(176)106261. https://doi.org/10.1016/j.rmed.2020.106261Test.; Sobieraj D.M., Weeda E.R., Nguyen E., Coleman C.I., White C.M., Lazarus S.C. et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496. https://doi.org/10.1001/jama.2018.2769Test.; Rogliani P., Ritondo B.L., Ora J., Cazzola M., Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020;56(3):2000625. https://doi.org/10.1183/13993003.00625-2020Test.; Beasley R., Harrison T., Peterson S., Gustafson P., Hamblin A., Bengtsson T., Fageras M. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma. A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. https://doi.org/10.1001/jamanetworkopen.2022.0615Test.; Bush A. Severe and Difficult Asthma: Diagnosis and ManagementChallenges for a Low-Resource Environment. Indian J Pediatr. 2022;89(2):156–162. https://doi.org/10.1007/s12098-021-03952-wTest.; Hodder R. The paradox of adult asthma control: “Who’s in control anyway?” Can Respir J. 2007;14(4):229–234. https://doi.org/10.1155/2007/975134Test.; Molimard M., Raherison C., Lignot M., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–254. https://doi.org/10.1089/089426803769017613Test.; Lavorini F., Magnan A., Dubus J.C., Voshaar T., Corbetta L., Broeders M. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604. https://doi.org/10.1016/j.rmed.2007.11.003Test.; Dudvarski Ilic A., Zugic V., Zvezdin B., Kopitovic I., Cekerevac I., Cupurdija V. et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Obstruct Pulmon Dis. 2016;(11):2509–2517. https://doi.org/10.2147/COPD.S114576Test.; Игнатова Г.Л., Белевский А.С. Современные способы ингаляционной доставки лекарств при лечении бронхообструктивных заболеваний. Астма и аллергия. 2018;(2):21–28. Режим доступа: https://atmosphere-ph.ru/modules.php?name=Magazines&sop=viewissue&magid=2&issueid=442Test.; Визель А.А., Белевский А.С., Визель И.Ю. К лечению бронхиальной астмы и хронической обструктивной болезнью легких: идем вперед с проверенными молекулами. Лечебное дело. 2020;(2):59–64. https://doi.org/10.24411/2071-5315-2020-12212Test.; Emeryk А., Pirożyński M., Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018;86(1):44–52. https://doi.org/10.5603/ARM.2017.0061Test.; https://www.med-sovet.pro/jour/article/view/7130Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-18-122-130Test
https://doi.org/10.1186/1471-2458-12-204Test
https://doi.org/10.1111/j.1398-9995.2004.00526.xTest
https://doi.org/10.1016/S0140-6736Test(12)61728-0
https://doi.org/10.1016/S0140-6736Test(12)61729-2
https://doi.org/10.1016/j.arbres.2014.12.007Test
https://doi.org/10.1183/09031936.00202013Test
https://doi.org/10.1016/S0140-6736Test(02)07953-9
https://doi.org/10.1016/j.jaci.2015.01.028Test
https://doi.org/10.1016/j.jaci.2012.03.044Test

المؤلفون: A. A. Vizel, I. Yu. Vizel

المصدر: Медицинский совет, Vol 0, Iss 15, Pp 99-104 (2019)

مصطلحات موضوعية: formoterol, budesonide, bronchial asthma, chronic obstructive pulmonary disease, generics, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/5428Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/7a36580026e84808928ece8538d6169fTest

المؤلفون: A. V. Emel’yanov, E. V. Leshenkova, G. R. Sergeyeva

المصدر: Медицинский совет, Vol 0, Iss 15, Pp 29-36 (2019)

مصطلحات موضوعية: mild bronchial asthma, budesonide, formoterol, intermittent administration, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/5228Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/b145f2fe75f94f33a829acca1ec5f081Test